FXR and BET signaling orchestrate to protect beta cells.

Return to Grants

Publication Year:
2026
Authors:
PubMed ID:
42039610
Public Summary:
Diabetes affects hundreds of millions of people worldwide and develops when the insulin-producing beta cells of the pancreas can no longer make enough insulin to maintain healthy blood sugar levels. Although type 1 and type 2 diabetes arise through different mechanisms, both involve inflammation, cellular stress, and the progressive dysfunction or loss of beta cells. Most current treatments help control blood sugar but do not directly prevent this underlying deterioration of beta-cell health. Identifying ways to protect these cells could therefore provide an important new strategy for slowing diabetes progression. This study reveals an unexpected connection between two biological systems that control how beta cells respond to stress. The first involves bile acids, naturally occurring molecules best known for helping digest fats but that also serve as important metabolic signals. Bile acid composition was found to be altered across multiple models of both type 1 and type 2 diabetes. The findings identify FXR, a protein that senses bile acids, as an important regulator that helps protect beta cells from inflammation and preserve their ability to produce and release insulin. The study further demonstrates that FXR interacts with BRD4, a protein that helps control which genes are turned on or off. This interaction establishes a previously unrecognized connection between metabolic signaling and the cellular machinery that regulates inflammation. Activating FXR while simultaneously blocking BET proteins, including BRD4, strongly reduced inflammatory responses, preserved beta-cell identity, and improved insulin secretion under conditions that normally damage beta cells. Importantly, these protective effects extended across several experimental models. In mouse models of type 2 diabetes, combined targeting of FXR and BET signaling improved blood sugar control, enhanced insulin secretion, preserved insulin-producing cells, and reduced damage within the pancreatic islets. When FXR was specifically removed from beta cells, these benefits were lost, demonstrating that beta-cell FXR plays a central role in the protective response. The therapeutic potential of this pathway was also examined in human stem-cell-derived pancreatic islet-like tissues designed to reproduce important features of type 1 and type 2 diabetes. Activating FXR together with selectively inhibiting a region of BET proteins known as BD2 protected human beta-like cells from inflammatory, metabolic, and immune-related damage. Together, these findings uncover a previously unrecognized pathway connecting bile-acid sensing, inflammation, and beta-cell survival. Rather than simply increasing insulin production, targeting this pathway could provide a strategy to preserve the body's own insulin-producing cells and maintain their function. Although further studies are needed to determine safety and effectiveness in people, these findings provide a foundation for developing new therapies aimed at protecting beta cells and potentially slowing the progression of both type 1 and type 2 diabetes.
Scientific Abstract:
In both type 1 and type 2 diabetes (T1D and T2D), insulin-producing beta cells undergo progressive dysfunction due to inflammation, leading to impaired glucose responsiveness, dedifferentiation, and cell loss. While bile acid (BA) dysregulation under diabetic conditions is known to influence metabolic and inflammatory pathways, its mechanistic role in beta cell regulation remains incompletely defined(1-3). Here we show that bile acid sensor Farnesoid X receptor (FXR) and Bromodomain and Extra-Terminal motif (BET) signaling cooperatively regulates beta cell inflammatory response and beta cell identity. We identified the physiological protein-protein interaction between FXR and the bromodomain-containing protein 4 (BRD4) as a regulatory axis that protects against beta cell dysfunction. We show that FXR activation by Fexaramine (Fex) together with BRD4 inhibition by JQ1 synergistically suppressed IL-1beta-induced inflammation while also improving beta cell identity and insulin secretion in both db/db model and high-fat diet (HFD) plus multi low-dose streptozotocin (MLD-STZ) model of diabetes. Importantly, this cooperative effect is abolished in beta cell-specific FXR knockout (betaFXRKO) mice, establishing that FXR is required for the functional synergy between these pathways in vivo. Mechanistically, structure-guided modeling and mutational analyses identified a direct interaction between FXR and the BD2 domain of BRD4, depending on specific lysine acetylation sites. Additionally, inhibition of the BD2 domain of BET combined with FXR activation markedly improved beta cell survival in human T1D and T2D models established from human pluripotent stem cell (hPSC)-derived islet-like organoids (HILOs). Collectively, these findings establish a BA-bromodomain axis as a transcriptional interface linking metabolic signaling and chromatin regulation, and highlight FXR-BET targeting as a promising strategy to counter progressive beta cell failure in diabetes.